title: Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
abstract: Hepatitis C virus common transmission routes and HCV coinfection is frequent in persons living with HIV. Liver enzyme elevation following the initiation of antiretroviral therapy is frequently seen in HIV-infected patients with chronic liver disease, particularly those with chronic hepatitis C. This complication may lead to treatment discontinuation, complicating HIV therapeutic management. Multiple factors influence the risk of liver toxicity under antiretroviral therapy, including the specific drug in use (e.g. use of full doses of ritonavir), and environmental factors (e.g. alcohol abuse). However a beneficial effect of antiretroviral therapy on liver disease has been supported by some studies. Despite increasing knowledge of HCV/HIV coinfection, there is no clear consensus on how to treat HIV in HCV-coinfected patients An Italian group of experts were invited to discuss in detail the current risks and implications of antiretroviral treatment in HIV-infected persons with chronic hepatitis C, and their main conclusions are summarized in this consensus document.
authors.affiliation: Department of Infectious Disease, University of Brescia, Brescia, Italy.
authors.forename: Giampiero
authors.initials: G
authors.lastname: Carosi
authors.forename: Massimo
authors.initials: M
authors.lastname: Puoti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Antonucci
authors.forename: Andrea
authors.initials: A
authors.lastname: De Luca
authors.forename: Renato
authors.initials: R
authors.lastname: Maserati
authors.forename: Carlo
authors.initials: C
authors.lastname: Torti
authors.forename: Paolo
authors.initials: P
authors.lastname: Bonfanti
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonora
authors.forename: Raffaele
authors.initials: R
authors.lastname: Bruno
authors.forename: Giovanni Battista
authors.initials: GB
authors.lastname: Gaeta
authors.forename: Andrea
authors.initials: A
authors.lastname: Antinori
authors.forename: Antonella d'Arminio
authors.initials: Ad
authors.lastname: Monforte
authors.forename: Anna
authors.initials: A
authors.lastname: Orani
authors.forename: Evangelista
authors.initials: E
authors.lastname: Sagnelli
authors.forename: Antonietta
authors.initials: A
authors.lastname: Cargnel
authors.forename: Roberto
authors.initials: R
authors.lastname: Cauda
authors.forename: Francesco
authors.initials: F
authors.lastname: Mazzotta
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pastore
authors.forename: Fredy
authors.initials: F
authors.lastname: Suter
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Vullo
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007558:Italy
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents